Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
An open-label, single-arm, pilot study of Venetoclax in combination
with 5-day courses of Azacitidine in treatment-nai¨ve subjects with acute myelogenous leukemia who are =18 years of age and not eligible for standard induction therapy - VENAZA-5S PILOT TRIAL
Description for laymen
An open-label, single-arm, pilot study of Venetoclax in combination
with 5-day courses of Azacitidine in treatment-nai¨ve subjects with acute myelogenous leukemia who are =18 years of age and not eligible for standard induction therapy - VENAZA-5S PILOT TRIAL
JSON Data
{
"short_title": "VENAZA-5S",
"data_mode": "910",
"data_mode_number": "000000028",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2022-501537-23-00",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Eine offene, einarmige Pilotstudie zu Venetoclax in Kombination mit 5-t\u00e4giger Azacitidin-Gabe bei therapienaiven Patienten mit \r\nakuter myeloischer Leuk\u00e4mie, die =18 Jahre alt sind und nicht f\u00fcr eine Standard-Induktionstherapie in Frage kommen - VENAZA-5S \r\nPILOT STUDIE",
"description_laie_en": "An open-label, single-arm, pilot study of Venetoclax in combination \r\nwith 5-day courses of Azacitidine in treatment-nai\u00a8ve subjects with acute myelogenous leukemia who are =18 years of age and not eligible for standard induction therapy - VENAZA-5S PILOT TRIAL",
"description_expert_de": "Eine offene, einarmige Pilotstudie zu Venetoclax in Kombination mit 5-t\u00e4giger Azacitidin-Gabe bei therapienaiven Patienten mit \r\nakuter myeloischer Leuk\u00e4mie, die =18 Jahre alt sind und nicht f\u00fcr eine Standard-Induktionstherapie in Frage kommen - VENAZA-5S \r\nPILOT STUDIE",
"description_expert_en": "An open-label, single-arm, pilot study of Venetoclax in combination \r\nwith 5-day courses of Azacitidine in treatment-nai\u00a8ve subjects with acute myelogenous leukemia who are =18 years of age and not eligible for standard induction therapy - VENAZA-5S PILOT TRIAL",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 30
}
